bluebird bio Announces Early Data from Phase 3 Northstar-2 (HGB-207) Study of LentiGlobinTM Drug Product at European Hematology Association (EHA) Annual Meeting
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, announced early interim data from the ongoing Northstar-2 (HGB-207) Phase 3 clinical study of LentiGlobin drug product in patients with transfusion-dependent β-thalassemia (TDT) and non-β0/β0 genotypes. These data will be presented by Mark Walters, M.D., UCSF Benioff Children’s Hospital, Oakland, California, in an oral session on Sunday, June 25 at the European Hematology Association (EHA) Annual Meeting in Madrid, Spain.
“Northstar-2 is our first study to utilize our improved LentiGlobin drug product manufacturing process to increase the drug product vector copy number and percent of cells transduced. The first patient treated in this study exemplifies the promise of gene therapy, discontinuing blood transfusions approximately a month after treatment and achieving a normal level of total hemoglobin production at six months post-treatment,” said David Davidson, M.D., chief medical officer, bluebird bio. “These early results suggest that the improved manufacturing process results in consistently higher drug product vector copy numbers (VCN) and lentiviral vector positive (LVV+) cells, which is correlated with higher production of HbAT87Q and ultimately may address known patient-to-patient variability.”
“Although early, these data add to the growing body of clinical evidence that indicate that LentiGlobin may offer a transformative benefit for patients with TDT,” said Alexis Thompson, MD, MPH, Ann & Robert H. Lurie Children’s Hospital of Chicago, Illinois and a primary investigator on the study. “Patients with TDT are dependent on a burdensome cycle of transfusion and chelation, and for these patients, gene therapy with LentiGlobin may offer a long-term solution with a one-time therapy that alleviates many of the complications of the current treatment paradigm.”
A Phase 3 Study to Evaluate Safety and Efficacy of LentiGlobin Gene Therapy for Transfusion-Dependent β-thalassemia in Patients with non-β 0 /β 0 Genotypes: The Northstar-2 (HGB-207) Trial (Abstract S814)
The Northstar-2 Study is an ongoing, open-label, single-dose, international, multicenter Phase 3 study designed to evaluate the safety and efficacy of LentiGlobin drug product for the treatment of patients with TDT and non-β0/β0 genotypes. As of June 2, 2017, drug product had been manufactured for six patients. The median DP VCN for these patients was 3.0 (range: 2.4 – 4.0), compared to a median DP VCN of 0.7 (range: 0.3 – 1.5) in Northstar. Results in treated patients, aged 20-22 years, as of June 2, 2017, include:
|Patient 1||Patient 2||Patient 3|
|DP VCN in each drug product lot (copies/diploid genome)||2.9||2.4||3.2, 2.4|
|LVV+ cells||77%||53%||77%, 82%|
|CD34+ cell dose (x106/kg)||7.0||13.6||8.1|
|HbAT87Q (g/dl; at last follow-up)||9.5||1.6||4.6|
|Total hemoglobin||13.3||Not reported||Not reported|
|Days since last transfusion||140||Not reported||Not reported|
|Follow-up||6 months||3 months||2 months|
- Follow-up on Patients 2 and 3 was not sufficient for total hemoglobin or days since last transfusion to be clinically relevant.
- The safety profile to date appears consistent with autologous transplantation. No Grade 3 or higher drug-product related adverse events have been observed.
bluebird bio will host a live webcast at 8:00 a.m. ET on Friday, June 23, 2017. The live webcast can be accessed under "Calendar of Events" in the Investors and Media section of the company's website at www.bluebirdbio.com. Alternatively, investors may listen to the call by dialing (844) 825-4408 from locations in the United States or (315) 625-3227 from outside the United States. Please refer to conference ID number 39917037.
About Northstar-2 (HGB-207)
Northstar-2 is a Phase 3, global, multi-center study designed to evaluate the safety and efficacy of LentiGlobin drug product in patients with transfusion-dependent beta-thalassemia and non-β0/β0 genotypes. For this study, the manufacturing process by which the patient’s cells are transduced with the LentiGlobin viral vector has been improved, with the intent of increasing vector copy number and the percentage of cells successfully transduced.
The target enrollment of the study is 15 adult and adolescent patients and 8 pediatric patients. The study’s primary endpoint is the proportion of treated subjects who meet the definition of "transfusion independence," defined as total hemoglobin levels of at least 9g/dL without any red blood cell (RBC) transfusions for a continuous period of at least 12 months at any time during the study.
Transfusion-dependent β-thalassemia (TDT), also called β-thalassemia major or Cooley’s anemia, is an inherited blood disease that can be fatal within the first few years of life if not treated.
Despite advances in the supportive conventional management of the disease, which consists of frequent and lifelong blood transfusions and iron chelation therapy, there is still a significant unmet medical need, including the risk for significant morbidity and early mortality. Currently, the only advanced treatment option for TDT is allogeneic hematopoietic stem cell transplant (HSCT). Complications of allogeneic HSCT include a significant risk of treatment-related mortality, graft failure, graft vs. host disease and opportunistic infections, particularly in patients who undergo non-sibling-matched allogeneic HSCT.
About bluebird bio, Inc.
With its lentiviral-based gene therapies, T cell immunotherapy expertise and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and cancer. bluebird bio’s gene therapy clinical programs include its Lenti-D™ product candidate, currently in a Phase 2/3 study, called the Starbeam Study, for the treatment of cerebral adrenoleukodystrophy, and its LentiGlobin™ product candidate, currently in four clinical studies for the treatment of transfusion-dependent β-thalassemia, and severe sickle cell disease. bluebird bio’s oncology pipeline is built upon the company’s leadership in lentiviral gene delivery and T cell engineering, with a focus on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR T) and T cell receptor (TCR) therapies. bluebird bio’s lead oncology program, bb2121, is an anti-BCMA CAR T program partnered with Celgene. bb2121 is currently being studied in a Phase 1 trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio also has discovery research programs utilizing megaTAL/homing endonuclease gene editing technologies with the potential for use across the company’s pipeline.
bluebird bio has operations in Cambridge, Massachusetts, Seattle, Washington and Europe.
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s research, development, manufacturing and regulatory approval plans for its LentiGlobin product candidate to treat transfusion-dependent ß-thalassemia, and whether the manufacturing process changes for LentiGlobin will improve outcomes of patients with transfusion-dependent ß-thalassemia. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that the preliminary positive efficacy and safety results from our prior and ongoing clinical trials of LentiGlobin will not continue or be repeated in our ongoing, planned or expanded clinical trials of LentiGlobin, the risks that the changes we have made in the LentiGlobin manufacturing process will not result in improved patient outcomes, risks that the current or planned clinical trials of LentiGlobin will be insufficient to support regulatory submissions or marketing approval in the US and EU, the risk of a delay in the enrollment of patients in our clinical studies, and the risk that any one or more of our product candidates, will not be successfully developed, approved or commercialized. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our most recent Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and bluebird bio undertakes no duty to update this information unless required by law.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Mobile Ticket Option Launches for Tampa Bay CityPASS17.10.2017 12:00 | Tiedote
City Pass, Inc., the company that specializes in packaging discounted admission to the most iconic attractions in 12 North American destinations, recently launched a mobile ticket option for its Tampa Bay CityPASS® program. Since 1997, CityPASS products have been designed to make travel easier and less expensive. And while the Tampa Bay CityPASS program will continue to excel at the latter—saving visitors 51 percent off combined admission to the included attractions—the new mobile ticket option dramatically enhances the convenience factor. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171017005538/en/ Busch Gardens Tampa Bay (Photo: SeaWorld Parks & Entertainment, Inc.) “We’re always looking for ways to improve the customer experience and make travel more convenient,” said CityPASS President a
Opus Trust Marketing Invests in Pitney Bowes’ Technology to Accelerate Growth17.10.2017 11:00 | Tiedote
Pitney Bowes Inc. (NYSE:PBI), a global technology company providing innovative products and solutions to power commerce, today announced that it has won a contract with Leicester-based Opus Trust Marketing. The contract will help Opus Trust accelerate growth and deliver its ambitious strategic development plans. Opus Trust specialises in multichannel communications, critical document printing and mailing for a diversity of high profile clients, including 20% of the FTSE 100. It is investing in Pitney Bowes’ Pulse™ inserting system as well as two of Pitney Bowes’ high-performance multi format inserters, Epic™. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171017005541/en/ The Pulse™ inserting system (Photo: Business Wire) Opus Trust is also investing its time in Pitney Bowes’ digital cus
NEC Europe Appoints Hironobu Kurosaki as President and CEO17.10.2017 11:00 | Tiedote
NEC Europe Ltd. today announced the appointment of Hironobu Kurosaki as President and CEO. In this role, Mr. Kurosaki will lead the growth of NEC Europe’s business for a broad range of customers spanning across its key business segments of Public Safety, Public IT services and Telecom Carrier Solutions in the EMEA region (Europe, the Middle East and Africa). Since joining NEC in 1983, Mr. Kurosaki has gained extensive international experience in the development of sales, marketing and strategy throughout the Americas and EMEA. In recent years, he has played a leading role in the development of NEC’s global business, where his experience as President of NEC Telecommunication and Information Technology Ltd. (Turkey), and contributions as General Manager of NEC’s Americas and EMEA Division have helped to deliver high-powered solutions and drive new growth in strategic ma
MagicStay, The Start-up of Short-Term Rental for Business, Affirms Its Ambitions at the Web Summit 201717.10.2017 11:00 | Tiedote
The French start-up MagicStay.com launched 3 years ago, now offers more than 130,000 apartments in 110 countries on its specialized platform for business travelers. As the only 100% B2B platform, MagicStay has developed many services adapted to the requirements of businesses, especially in terms of security and integration into their tools, which will be presented at the Web Summit in Lisbon from 6 to 9 November. For three years now, the start-up has been developing an exclusive technology that makes it possible to provide a global supply of short-term rentals in immediate reservations. These professionally managed accommodations meet corporate requirements: security, legislation compliance, and integration into booking tools used by corporate companies. "The Business Travel Market is very complex in terms of technology and actors, and is highly
Sigma Systems Appoints Vladimir Mitrasinovic as Senior Vice-President of Sales and Managing Director for EMEA and APAC17.10.2017 11:00 | Tiedote
Sigma Systems, the leader in catalog-driven software, has appointed Vladimir Mitrasinovic as Senior Vice-President of Sales and Managing Director for EMEA and APAC. Mr. Mitrasinovic was previously Head of the Cloud and Software as a Service business unit for Cerillion Technologies, and served as Executive Vice-President of Global Channels and Alliances at Acision (XURA). As Senior Vice President of Sales and Managing Director of EMEA and APAC, Vladimir will oversee all sales and business development efforts within the regions. “We are delighted to welcome Vladimir to the Sigma team,” said Simon Muderack, Sigma’s Executive Vice President and Chief Commercial Officer. “Vladimir’s background in high-growth corporate development in the technology sector and experience in sales and business expansion will be an excellent asset to Sigma as we continue to expand across EMEA and
REFLEX CES Partners with NOLAM EMBEDDED SYTEMS to Provide Integrated CANbus IP Core Solutions on FPGA COTS Boards17.10.2017 10:00 | Tiedote
NOLAM EMBEDDED SYSTEMS, manufacturer of semiconductor IP and board level products and systems for the Aerospace, Defense, telecom and industrial markets, today announced their partnership with REFLEX CES, a leading provider of complex, high-density FPGA-based boards. This partnership benefits customers by providing them a fully integrated solution based on REFLEX CES FPGA boards and NOLAM EMBEDDED SYSTEMS CANbus IP core and CANbus FMC module. «We are thrilled to collaborate with REFLEX CES to offer a fully integrated CANbus solution», stated Benjamin Nakache, Vice-President of Sales at Nolam Embedded Systems «By integrating our CANbus IP solution with our CANbus FMC to the REFLEX CES hardware, we bring a very easy-to use solution to CANbus users in the automotive industry.» One of the first outcomes of this collaborative venture is the release of an SDK, composed of REF
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme